

K994001

FEB 9 2000

T.CAD International
990927/MG-510(k)
POLYGLYCOLIC ACID

SECTION III

510(K) Summary of Safety and Effectiveness

This summary of safety and effectiveness information is being submitted in accordance with the requirements of the Safe Medical Devices Act (SMDA) of 1990 and Title 21 CFR §807.92

A. Applicant & Submitted by:

Trading Consultants And Distributors International Inc.
(T.CAD International)
157 WindDance Dr.
Chicago, IL 60046-6681
Telephone: (847) 265-7676
Fax: (847) 265-7686

Contact Person: Main M. Ghazal
Date Prepared: September 27th 1999.

B. Device Name:

- a. Trade Name: POLYGLYCOLIC ACID
- b. Common or Usual Name: Polyglycolic Acid Surgical Suture
- c. Classification Name: Absorbable Poly (glycolide/L-lactide) Surgical Suture (Per 21CFR878.4493)

C. Predicate Device:

DEXON II® Polyglycolic Acid Surgical Suture, Davis & Geck (K972566)
Ethicon Absorbable Poly (L-lactide/glycolide) Surgical Suture, Undyed.
(K964345)

D. Device Description:

POLYGLYCOLIC ACID is a synthetic absorbable sterile surgical suture composed of a synthetic polyglycolic acid polymer and is indicated for use in general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular and neurological procedures. POLYGLYCOLIC ACID meets all requirements as described in the United States Pharmacopeia (U.S.P.) monograph for Absorbable Surgical Suture. Offered as monofilament or multifilament in form, and it is offered uncoated or coated with polycarpolactone and calcium stearate, it could also be undyed or dyed with an FDA listed color additive, D&C Violet No. 2 (21CFR74.3602). POLYGLYCOLIC ACID will be offered with or without standard needles attached.

E. Intended Use: POLYGLYCOLIC ACID is indicated for use in general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular and neurological procedures.

T.CAD International
990927/MG-510(k)
POLYGLYCOLIC ACID

F. Comparison to Predicate Device:

	POLYESTER	Predicate Device
Intended Use	General soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular and neurological procedures.	Same
Suture Material	Composed of glycolide polymer.	Ethicon: Composed of copolymers made of glycolide and L-lactide Davis & Geck: composed of glycolide polymer.
Suture Characteristics	Retains approximately 65% of its original tensile strength at two weeks post implantation, with approximately 40% remaining at three weeks. Absorption of the suture is essentially complete between 60 and 90 days.	Same.
Sterilization Method	Ethylene Oxide Gas	Same or equivalent process.
How Supplied	Monofilament or Braided, coated with polycaprolactone & calcium stearate or uncoated, undyed or dyed with D&C Violet No. 2. Sterile and offered for Single Use Only with or without needle.	Same or equivalent manner. Both Predicate devices are offered Braided. Both are coated with Polycaprolactone; a copolymer of caprolactone and glycolide. Davis & Geck is dyed with D&C violet No. 2. Ethicon is undyed.
Suture Diameter, Suture Length, Knot Pull Tensile Strength and Needle Attachment Strength	Meet U.S.P. Requirements	Meet U.S.P. Requirements
Packaging	Dry packaged in Aluminum Foil and Polyester tear open packaging.	Same or equivalent manner.
Labeling	In conformance with CDRH instructions of the "Medical Device Quality Manual" dated December 1996. Package Inserts in accordance with the FDA Guidance documents "Alternate Suture Labeling" Resulting from the January 11 th 1993 meeting with HIMA, reformatted on December 17 th 1997.	Same

T.CAD International
990927/MG-510(k)
POLYGLYCOLIC ACID

G. Clinical & Non-Clinical Testing:

Non-Clinical Testing was conducted on the subject device to prove conformance to the requirements of U.S.P. standards and to demonstrate substantial equivalence to the predicate device. Physical properties and functionality testing assured the safety and effectiveness of the subject device within its intended uses. Results of the non-clinical testing demonstrate conformance with the U.S.P. standards and requirements for Absorbable surgical suture.

Clinical Testing: Not available at the present time.

H. Conclusion:

Based on the technological characteristics and physical properties of the device, the device description, the intended use of the device, and conformance with voluntary performance standards like:

- a. United States Pharmacopeia Standards
- b. ISO 9002 & EN 46002.
- c. FDA Guidance documents "Alternate Suture Labeling" Resulting from the January 11th 1993 meeting with HIMA.

T.CAD International believes that the subject device demonstrates a substantial equivalence to the predicate device.



FEB - 9 2000

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Main M. Ghazal
Trading Consultants and Distributors International, Inc.
157 WindDance Drive
Chicago, Illinois 60046-6681

Re: K994001
Trade Name: Polyglycolic Acid
Regulatory Class: II
Product Code: GAM
Dated: November 22, 1999
Received: November 24, 1999

Dear Mr. Ghazal:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices that were regulated as transitional devices and that have been reclassified into class II. Notice of this reclassification was published in the Federal Register on Wednesday, September 18, 1991 (Vol. 56, No. 18, Pages 47150 and 47151). A copy of this Federal Register can be obtained by calling the Division of Small Manufacturers Assistance (DSMA) at (800) 638-2041 or (301) 443-6597. You may, therefore, market the device subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act) and the following limitations:

1. The Polyglycolic Acid Surgical Suture is indicated for use in general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular and neurological procedures.
2. This device may not be manufactured from any material other than homopolymers and copolymers made from glycolide and/or L-lactide. Any deviation of the polymer composition or processing as described in this 510(k) notification must be submitted to FDA in a new premarket notification at least 90 days prior to implementation of the proposed change(s). In addition, you must maintain documentation at your premises regarding vendor certification for raw or semiprocessed source material, all manufacturing and quality control release procedures, and validation of sterilization procedures used in the manufacturing of the Polyglycolic Acid surgical suture. Any deviation of the source material or processing as described in this 510(k) notification requires submission of a new premarket notification and Food and Drug Administration (FDA) clearance prior to commercial distribution of the modified device.

The sale, distribution and use of this device are restricted to prescription use in accordance with 21 CFR 801.109.


The general controls provisions of the Act include requirements for registration, listing of devices, good manufacturing practice, and labeling, and prohibition against misbranding and adulteration.

Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



James E. Dillard III *for JED*
Acting Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K994001

T.CAD International
990927/MG-510(k)
POLYGLYCOLIC ACID

SECTION II

Statement of indication for use

Device Name: POLYGLYCOLIC ACID

510(k) Number:

Indication for use:

POLYGLYCOLIC ACID is indicated for use in general soft tissue approximation and/or ligation, including use in ophthalmic procedures, but not for use in cardiovascular and neurological procedures.

(PLEASE DO NOT WRITE BELOW THE LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-the-Counter Use _____
(Per 21CFR 801.109)

(Division Sign-Off) *M40 for J2D*
Division of General Restorative Devices
510(k) Number K994001